Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. INSM
stocks logo

INSM

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
171.87M
+64.56%
-1.281
-2.95%
194.78M
+109.84%
-1.231
-13.29%
259.84M
+141.91%
-1.070
-37.06%
Estimates Revision
The market is revising Upward the revenue expectations for Insmed Incorporated (INSM) for FY2025, with the revenue forecasts being adjusted by 7.48% over the past three months. During the same period, the stock price has changed by 36.44%.
Revenue Estimates for FY2025
Revise Upward
up Image
+7.48%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+10.26%
In Past 3 Month
Stock Price
Go Up
up Image
+36.44%
In Past 3 Month
Wall Street analysts forecast INSM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INSM is 200.31 USD with a low forecast of 145.00 USD and a high forecast of 240.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
Wall Street analysts forecast INSM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INSM is 200.31 USD with a low forecast of 145.00 USD and a high forecast of 240.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 200.130
sliders
Low
145.00
Averages
200.31
High
240.00
Current: 200.130
sliders
Low
145.00
Averages
200.31
High
240.00
Rothschild & Co Redburn
Buy
initiated
$263
2025-12-04
New
Reason
Rothschild & Co Redburn
Price Target
$263
2025-12-04
New
initiated
Buy
Reason
Rothschild & Co Redburn initiated coverage of Insmed with a Buy rating and $263 price target. The firm believes the company is well positioned in "large" therapy areas with limited competition. The company's of Brinsupri, a first-in-class therapy for bronchiectasis, should see strong uptake given the lack of competitors, the analyst tells investors in a research note. Rothschild thinks Brinsupri has peak sales of $12B, above the consensus median of $10B.
TD Cowen
Ritu Baral
Buy
maintain
$223 -> $231
2025-11-20
Reason
TD Cowen
Ritu Baral
Price Target
$223 -> $231
2025-11-20
maintain
Buy
Reason
TD Cowen analyst Ritu Baral raised the firm's price target on Insmed to $231 from $223 and keeps a Buy rating on the shares. The firm said Brinsupri, the company's 1st-gen neutrophil elastase inhibitor, received formal EC approval for NCFBE 'with 2+ exacerbations' in the prior year. Insmed will secure access starting early 2026, likely with an initial German launch.
Goldman Sachs
Buy
maintain
$196 -> $225
2025-11-03
Reason
Goldman Sachs
Price Target
$196 -> $225
2025-11-03
maintain
Buy
Reason
Goldman Sachs raised the firm's price target on Insmed to $225 from $196 and keeps a Buy rating on the shares.
Truist
Buy
maintain
$139 -> $214
2025-11-02
Reason
Truist
Price Target
$139 -> $214
2025-11-02
maintain
Buy
Reason
Truist raised the firm's price target on Insmed to $214 from $139 and keeps a Buy rating on the shares. The company's Q3 results showcased Insmed's robust commercial execution with two commercial products beating consensus expectations, and the firm expects concerns around market access for Brinsupri to eventually be resolved as physician awareness of this first in disease therapy increases, the analyst tells investors in a research note.
RBC Capital
Leonid Timashev
Outperform
maintain
$139 -> $215
2025-10-31
Reason
RBC Capital
Leonid Timashev
Price Target
$139 -> $215
2025-10-31
maintain
Outperform
Reason
RBC Capital analyst Leonid Timashev raised the firm's price target on Insmed to $215 from $139 and keeps an Outperform rating on the shares after its Q3 results. The firm is impressed by Brinsupri's early commercial performance in bronchiectasis that handily beat expectations, and based on key opinion leader feedback and early signs, RBC remains confident that the trajectory is sustainable, the analyst tells investors in a research note.
Goldman Sachs
Buy
maintain
$196 -> $225
2025-10-31
Reason
Goldman Sachs
Price Target
$196 -> $225
2025-10-31
maintain
Buy
Reason
Goldman Sachs raised the firm's price target on Insmed to $225 from $196 and keeps a Buy rating on the shares. The stock significantly outperformed following an "impressive" Brinsupti beat in non-CF bronchiectasis, the analyst tells investors in a research note. Goldman views Insmed as an attractive growth story on the forward.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Insmed Inc (INSM.O) is -44.54, compared to its 5-year average forward P/E of -10.51. For a more detailed relative valuation and DCF analysis to assess Insmed Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-10.51
Current PE
-44.54
Overvalued PE
-2.54
Undervalued PE
-18.49

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-11.94
Current EV/EBITDA
-51.05
Overvalued EV/EBITDA
-3.07
Undervalued EV/EBITDA
-20.81

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Overvalued
5Y Average PS
18.20
Current PS
46.04
Overvalued PS
29.07
Undervalued PS
7.34
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

INSM News & Events

Events Timeline

(ET)
2025-12-01
07:19:00
Mizuho Raises Insmed Price Target to $256, Maintains Outperform Rating
select
2025-11-18 (ET)
2025-11-18
11:02:00
Insmed's Brinsupri Receives EU Approval for Treatment of Non-Cystic Fibrosis Bronchiectasis
select
2025-10-30 (ET)
2025-10-30
07:35:28
Insmed increases 2025 global revenue forecast for Arikayce to $420M-$430M, up from $405M-$425M
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
12-04PRnewswire
Insmed Grants Inducement Awards to 92 New Employees, Including 44,273 Restricted Stock Units
  • Employee Incentive Program: Insmed granted inducement awards to 92 new employees, including 44,273 restricted stock units and options for 2,490 shares, aimed at attracting top talent and enhancing employee loyalty.
  • Stock Option Details: The options have an exercise price of $207.77 per share, compliant with Nasdaq listing rules, which is expected to enhance long-term employee incentives and company performance.
  • Grant Conditions: Both the restricted stock units and stock options have a four-year vesting schedule, ensuring that employees contribute continuously during their tenure, thereby enhancing team stability.
  • Company Background: Insmed focuses on developing innovative therapies for serious diseases, committed to meeting patient needs and strengthening its competitive position in the biopharmaceutical industry.
[object Object]
Preview
5.0
12-04Newsfilter
Insmed Grants Inducement Awards to 92 New Employees with 44,273 Restricted Stock Units
  • Employee Incentive Program: Insmed has granted inducement awards to 92 new employees, comprising 44,273 restricted stock units and options for 2,490 shares, aimed at attracting top talent and enhancing employee loyalty.
  • Stock Option Details: The options have an exercise price of $207.77 per share, based on the closing price on the grant date, which is expected to enhance long-term employee incentives and company performance.
  • Vesting Arrangements: Both the restricted stock units and options are subject to a four-year vesting schedule, ensuring that employees contribute continuously during their tenure, thereby promoting team stability and business continuity.
  • Strategic Company Positioning: This incentive initiative reflects Insmed's commitment to talent, aiming to drive innovation and market competitiveness in the biopharmaceutical sector by attracting and retaining key personnel.
[object Object]
Preview
6.0
12-01Benzinga
Amazon Set to Surge by 31%? Check Out 10 Leading Analyst Predictions for Monday

  • Analyst Upgrades and Downgrades: JP Morgan downgraded Argan Inc while raising its price target, Oppenheimer maintained an Outperform rating for Amazon with a price target increase, and RBC Capital downgraded PTC Therapeutics despite raising its price target.

  • Price Target Adjustments: Barclays lowered Crown Castle's price target and downgraded its rating, while Benchmark raised Light & Wonder's target and maintained a Buy rating.

  • Significant Increases: Mizuho raised Insmed's price target significantly and maintained an Outperform rating, while HSBC upgraded Thermo Fisher Scientific from Hold to Buy with a notable price target increase.

  • Mixed Ratings: Argus Research cut Target's price target but kept a Buy rating, and BMO Capital reduced Old Dominion's target while upgrading its rating to Outperform.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Insmed Inc (INSM) stock price today?

The current price of INSM is 200.13 USD — it has decreased -1.9 % in the last trading day.

arrow icon

What is Insmed Inc (INSM)'s business?

Insmed Incorporated is a global biopharmaceutical company. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company’s pre-clinical research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 as well as pre-clinical research programs.

arrow icon

What is the price predicton of INSM Stock?

Wall Street analysts forecast INSM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INSM is 200.31 USD with a low forecast of 145.00 USD and a high forecast of 240.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Insmed Inc (INSM)'s revenue for the last quarter?

Insmed Inc revenue for the last quarter amounts to 142.34M USD, increased 52.36 % YoY.

arrow icon

What is Insmed Inc (INSM)'s earnings per share (EPS) for the last quarter?

Insmed Inc. EPS for the last quarter amounts to -1.75 USD, increased 37.80 % YoY.

arrow icon

What changes have occurred in the market's expectations for Insmed Inc (INSM)'s fundamentals?

The market is revising Upward the revenue expectations for Insmed Incorporated (INSM) for FY2025, with the revenue forecasts being adjusted by 7.48% over the past three months. During the same period, the stock price has changed by 36.44%.
arrow icon

How many employees does Insmed Inc (INSM). have?

Insmed Inc (INSM) has 1271 emplpoyees as of December 09 2025.

arrow icon

What is Insmed Inc (INSM) market cap?

Today INSM has the market capitalization of 43.51B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free